High Cost of New Drugs Weighs on Medicaid


A U.S. District Court case highlights concerns over the high costs of specialty drugs such as Kalydeco, which treats some cystic fibrosis patients at an approximate annual cost of $300,000.

Want the Full Article?

Get Unlimited Archive Access for $19.95 per Year

Readers must pay to access articles older than 15 days.
Articles newer than 15 days are not included in this offer.

Purchase Now

Already have archive access? Login to view this article.